Products

TruSight Oncology 500

Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB). Read More...

This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.

Select Product(s)
What do I need?
Manual Prep

TruSight Oncology 500 HRD Kit (24 samples)

20076480

TruSight Oncology 500 DNA Kit (48 samples)

20028213

Price
 
 

TruSight Oncology 500 DNA Kit, For Use with NextSeq (48 samples)

20028214

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, (16 indexes, 24 samples)

20028215

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, for use with NextSeq (16 indexes, 24 samples)

20028216

Price
 
 

TruSight Oncology 500 DNA Kit plus Pierian interpretation report (16 indexes, 48 Samples)

20032624

Price
 
 

TruSight Oncology 500 DNA Kit for Use with NextSeq plus Pierian interpretation report (16 indexes, 48 Samples)

20032625

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle plus Pierian interpretation report (16 indexes, 24 Samples)

20032626

Price
 
 

TruSight Oncology 500 DNA/RNA Kit for Use with NextSeq plus Pierian interpretation report (16 indexes, 24 Samples)

20032627

Price
 
 
Automation

TruSight Oncology 500 DNA Automation Kit (16 indexes, 64 Samples)

20045504

Price
 
 

TruSight Oncology 500 DNA Automation Kit, For Use with NextSeq (16 indexes, 64 Samples)

20045505

Price
 
 

TruSight Oncology 500 DNA Automation Kit plus Pierian interpretation report (16 indexes, 64 samples)

20045506

Price
 
 

TruSight Oncology 500 DNA Automation Kit plus Pierian interpretation report, for Use with NextSeq (16 indexes, 64 samples)

20045507

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit (16 indexes, 32 Samples)

20045508

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit plus Pierian interpretation report (16 indexes, 32 Samples)

20045509

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit, For Use with NextSeq (16 indexes, 32 Samples)

20045990

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit plus Pierian interpretation report, For Use with NextSeq (16 indexes, 32 Samples)

20045991

Price
 
 
Services

TruSight Oncology 500 Training (DNA, optional HRD) - Customer Site

20031667

Price
 
 

TruSight Oncology 500 Training (DNA and RNA, optional HRD) - Customer Site

20031668

Price
 
 
Software and Informatics Options

Illumina DRAGEN Server v3

20040619

Illumina DRAGEN Server v4

20051343

Price
 
 

DRAGEN TruSight Oncology 500 HRD Analysis Software, On-Premise

20073738

ICA Basic Annual Subscription

20044874

ICA Professional Annual Subscription

20044876

ICA Enterprise Annual Subscription

20038994

ICA Enterprise Service and Compliance Add-on (applies to Basic only)

20066830

Illumina Analytics - 1 iCredit

20042038

Price
 
 

Illumina Analytics  Starter Pack - 1,000 iCredits

20042039

Price
 
 

Illumina Analytics  - 5,000 iCredits

20042040

Price
 
 

Illumina Analytics  - 50,000 iCredits

20042041

Price
 
 

Illumina Analytics - 100,000 iCredits

20042042

Price
 
 

Illumina Connected Insights-Annual Subscription

20090137

Illumina Connected Insights‒Oncology Genome Equivalent Sample-VCF

20090138

Illumina Connected Insights‒Training and Onboarding

20092376

Informatics Professional Services

20071787

Add To Cart
Total:

TruSight Oncology 500

Product Highlights

TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports identification of all relevant DNA and RNA variants implicated in various solid tumor types.

In addition, it accurately measures key current immuno-oncology biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Oncology 500 HRD* is an optional add-on kit to TruSight Oncology 500 and enables detection of homologous recombination deficiency (HRD) through assessment of a genomic instability score (GIS). This represents an exciting new advancement to the TruSight Oncology portfolio.

*Not available in Japan.

Consolidate Multiple Biomarker Assays into One

  • Pan-cancer biomarker content aligned with key guidelines and clinical trials
  • 523 genes for assessment of all DNA and RNA variant types, plus microsatellite instability (MSI), tumor mutational burden (TMB) and homologous recombination deficiency (HRD)
  • Optional add-on HRD enrichment kit to assess loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large scale state transitions (LST) in one genomic instability (GIS) score, powered by Myriad Genetics.
  • Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay

Streamlined Sample-to-Results Workflow

  • Go from initial sample to results in 4-5 days
  • Rapid variant calling algorithm powered by DRAGEN pipelines, available locally on DRAGEN server
  • Secure, scalable, cloud-based variant calling is available with DRAGEN pipelines on Illumina Connected Analytics (ICA) featuring auto-launch capability.
  • Automation kits and methods available for reduced hands-on time and increased scalability. (Not available for TruSight Oncology 500 HRD.)
  • Multiple verified tertiary analysis options available, including Illumina Connected Insights† and Pierian Clinical Genomics Workspace

† Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.

Achieve Highly Confident Results

  • Hybrid-capture chemistry combined with sophisticated bioinformatics, leading to high analytical specificity and sensitivity
  • Inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
  • Based on proven Illumina SBS sequencing technology

Enable In-House Comprehensive Genomic Profiling

  • Keep samples and data in house, for more control and ability to build a database
  • A future-proof assay with emerging biomarkers already included

Fast, Automation-friendly Workflow

Prepare libraries for Illumina sequencing in less than a day. Illumina Qualified Methods are available on a range of automation platforms through our partners.

Learn more about the TruSight Oncology Product Family

TruSight Oncology 500 Portfolio

All three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.

TruSight Oncology 500 Assay

Assess relevant biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.

TruSight Oncology 500 High-Throughput Assay

Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA Assay

Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.

Purchasing the TruSight Oncology 500 assay for the first time?

Complete the form to receive information about the first-time TruSight Oncology 500 purchase program.

Frequently Purchased Together

Specifications

Product Comparison

TruSight Oncology 500 TruSight Oncology 500 High-Throughput TruSight Oncology 500 ctDNA
Cancer Type Pan-Cancer Pan-Cancer Pan-Cancer
Content Specifications Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 1,000 clinical trials
• Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*
• TruSight Oncology 500 HRD** kit content includes coverage of ~25,000 SNP's to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST), powered by Myriad Genetics
• TruSight Oncology 500 HRD** is an optional add-on kit to TruSight Oncology 500

**Not available in Japan		 Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.
• Immuno-oncology Biomarker Coverage: TMB and MSI
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 600 clinical trials*		 Targeted selection of 523 genes (full coding sequence) for a total of 1.94Mb panel size.
• Immuno-oncology Biomarker Coverage: TMB and MSI
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 600 clinical trials*
Hands-On Time Manual: ~10.5 hrs
Automated: ~2.5 hrs (TruSight Oncology 500 only)		 Manual: ~10.5 hrs
Automated: ~2.5 hrs		 Manual: ~10.5 hrs
Automated: N/A
Input Quantity 40 ng DNA, 40 ng RNA 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) 30 ng cfDNA (8-10 ml of plasma)
Method Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing Target Enrichment, Target Enrichment, Targeted DNA Sequencing
Nucleic Acid Type RNA, DNA RNA, DNA DNA
Specialized Sample Types FFPE Tissue FFPE Tissue Blood, Circulating Tumor DNA
Species Category Human Human Human
System Compatibility NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode NovaSeq 6000, NovaSeq 6000Dx in Research Mode NovaSeq 6000, NovaSeq 6000Dx in Research Mode
Technology Sequencing Sequencing Sequencing
Variant Class Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Somatic Variants

* Based on Pierian clinical knowledgebase, as of February 2023.

† NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.

Analytical Evaluation & Verification Service

The TruSight Oncology 500 Analytical Evaluation Service* is a set of tools intended to guide you in aligning with the latest CAP, AMP, and European standards. We provide recommendations to help you evaluate analytical performance characteristics and integrate products into your workflows.

Learn More
Analytical Evaluation & Verification Service

* This service is available in select countries and regions.

Method-Specific Workflow Example

 
Prepare Library for:
Targeted Cancer Sequencing
 
Sequence Efficiently with:
NextSeq 550 System
NextSeq 550Dx in Research Mode
 
Analyze Your Data with:

Variant Calling:

DRAGEN Bio-IT Platform: on-premise via DRAGEN server
DRAGEN Bio-IT Platform: cloud-based via Illumina Connected Analytics, ICA
TruSight Oncology 500 Local App: Docker-based Software
Local Run Manager: On-instrument Software

Insights and report generation

Illumina Connected Insights*
Pierian Clinical Genomics Workspace Software

* Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.

 

Supporting Data and Figures

 
Pan-cancer: BRAF, NTRK1, NTRK2, NTRK3, RET, MSI, TMB
Genes with biomarkers of significance* Genes with biomarkers of potential significance†
breast cancer
Breast		 BRCA1 BRCA2 ERBB2 ESR1 PALB2 PIK3CA         180
colorectal cancer
Colorectal		 ERBB2 KRAS NRAS               166
bone cancer
Bone		 EGFR ERG ETV1 ETV4 EWSR1 FEV FLI1 FUS H3F3A HEY1 140
IDH1 MDM2 NCOA2 SMARCB1            
lung cancer
Lung		 ALK EGFR ERBB2 KRAS MET NUTM1 ROS1       223
melanoma cancer
Melanoma		 KIT NRAS ROS1               172
ovarian cancer
Ovarian		 BRCA1 BRCA2 FOXL2               149
cns cancer
CNS		 APC ATRX CDKN2A CDKN2B EGFR H3F3A HIST1H3B HIST1H3C IDH1 IDH2 140
MYCN PTCH1 RELA TERT TP53          
prostate cancer
Prostate		 AR ATM BARD1 BRCA1 BRCA2 BRIP1 CDK12 CHEK1 CHEK2 FANCL 151
FGFR2 FGFR3 PALB2 RAD51B RAD51C RAD51D RAD54L      
thyroid cancer
Thyroid		 HRAS KRAS NRAS RET TERT           165
uterine cancer
Uterine & cervical		 BRCA2 EPC1 ERBB2 ESR1 FOXO1 GREB1 JAZF1 NCOA2 NCOA3 NUTM2A 138
NUTM2B PAX3 PAX7 PHF1 POLE SMARCA4 SUZ12 TP53 YWHAE  
other solid cancer tumors
Other Solid Tumors		 ALK APC ARID1A ASPSCR1 ATF1 ATIC BAP1 BCOR BRCA1 BRCA2 152
CAMTA1 CARS CCNB2 CDK4 CDKN2A CIC CITED2 CLTC COL1A1 COL6A3
CREB1 CREB3L1 CREB3L2 CSF1 CTNNB1 DDIT3 DDX3X DNAJB1 DUX4 EED
EGFR ERBB2 ERG ETV1 ETV4 ETV6 EWSR1 FEV FGFR2 FGFR3
FLI1 FOXL2 FOXO1 FOXO4 FUS GLI1 HEY1 HGF HMGA2 IDH1
KRAS LEUTX MAML3 MDM2 MYB MYOD1 NAB2 NCOA2 NF1 NFATC2
NFIB NR4A3 NRAS NUTMI NUTM2A NUTM2B PALB2 PATZ1 PAX3 PAX7
PDGFB PDGFRA PRKACA PRKD1 RANBP2 ROS1 SDHA SDHB SDHC SDHD
SMARCB1 SS18 SSX1 SSX2 SSX4 STAT6 SUZ12 TAF15 TCF12 TERT
TFE3 TFEB TFG TP53 TPM3 TPM4 TRAF7 TSPAN31 VGLL2 WT1
WWTR1 YAP1 YWHAE ZC3H7B            

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on this page.

* The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.

Product Literature

Simplifying the process to identify applicable variants in oncology samples

Brochure | PDF 2 MB

Analysis of TMB and MSI Status with TruSight Oncology 500

Application Note | HTML

Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput

Technical Note | PDF < 1 MB

Input Recommendations for TMB, MSI, and Small Variant Analysis with TruSight Oncology 500

Technical Note | HTML

TruSight Oncology 500 Gene List

product_file | EXCEL < 1 MB

Data analysis and reporting for the TruSight Oncology 500 portfolio

Product Information Sheet | PDF 1 MB

Data Sheet | PDF | 7 versions

Data Sheet | PDF | 6 versions

Manuals and Support Information

DRAGEN TruSight Oncology 500 Analysis Software v1.1 Documentation

TruSight Oncology 500 v1.0 Local App Documentation

TruSight Oncology 500 v2.0 Local App Documentation

TruSight Oncology 500 v2.1 Local App Documentation

DRAGEN TruSight Oncology 500 Analysis Software v2.1 Documentation

DRAGEN TruSight Oncology 500 Analysis Software v1.1 on ICA Documentation

DRAGEN TruSight Oncology 500 Analysis Software v2.1.2 on ICA Documentation

DRAGEN TruSight Oncology 500 Analysis Software v2.1.1 on ICA Documentation

TruSight Oncology 500 Support Documentation

TruSight Oncology 500 v2.2 Local App Documentation

All TruSight Oncology 500  Support  

Related Products

Related Solutions

Back to Top  
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2023 Illumina, Inc. All rights reserved.